Aptorum Group Announces Collaboration Between DiamiR And AlzLabs Precision Diagnostics To Generate Protein And MicroRNA Blood-Based Biomarker Data With Focus On Alzheimer's Disease

As was previously announced on July 16, 2025, Aptorum Group and DiamiR entered into a definitive agreement for an all-stock merger transaction. On June 9, 2026 shareholders of both companies approved the merger. 

The completion of the merger remains subject to the satisfaction or waiver of the remaining customary closing conditions described in the merger agreement. The companies currently expect the transaction to close before fiscal 2027. 

Upon closing of the merger, DiamiR will become a wholly-owned subsidiary of Aptorum Group, and the combined company will be renamed Niki BioSolutions, Inc.